Circuit Says Claims Against Makers Of Generic Fosamax Are Preempted

, New Jersey Law Journal


The U.S. Court of Appeals for the Third Circuit affirms dismissal of claims against generic manufacturers of the bone-loss prevention drug Fosamax as preempted by federal law.

What's being said

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article# 1202653371606

Thank you!

This article's comments will be reviewed.